Month: September 2024

Smoking Cessation Treatment Market Size was ~USD 1800 Million in 2022, estimated DelveInsight

“Smoking Cessation Therapies such as Bupropion, Zonisamide, Cytisinicline, Nicoderm, Varenicline, and others”

The Smoking Cessation Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Smoking Cessation therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

DelveInsight’s “Smoking Cessation Market Insight, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of Smoking Cessation, historical and forecasted epidemiology as well as the Smoking Cessation market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Key Takeaways from the Smoking Cessation Market Report

  • The increase in market size is a direct consequence of expected approval of emerging therapies and increasing diagnosed prevalent population of Smoking Cessation in the 7MM.

  • The leading Smoking Cessation Companies such as Rose Research Center LLC, Achieve Life Sciences, NFL Biosciences SAS, and others.

  • Promising Smoking Cessation Therapies such as Bupropion, Zonisamide, Cytisinicline, Nicoderm, Varenicline, and others.

  • As per DelveInsight’s assessment, the diagnosed prevalence of smoking is higher in males as compared to females.

  • As per DelveInsight analysts, the total diagnosed prevalent cases of Smoking Cessation in the 7MM was 50,899,152 in 2022.

  • August 2024:- Rose Research Center, LLC- combination zonisamide and bupropion on the process of switching from combustible cigarettes (CCs) to an e-cigarette. There will be a data collection period of at least five days to obtain baseline information on the use of combustible cigarettes.

Gain a competitive edge in the Smoking Cessation Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Smoking Cessation Treatment Drugs

Smoking Cessation Treatment Market

There are effective treatments that support tobacco cessation, including both behavioral therapies and medications. There are 89 distinct products and services available today for smoking cessation, alongside 12 smoking alternatives that are not specifically indicated for cessation. FDA-approved pharmacotherapies include various forms of nicotine replacement therapy (NRT) in the form of a transdermal patch, gum, nasal spray, oral inhaler, and lozenges; bupropion; and, most recently, varenicline. Nortriptyline and clonidine have been shown in clinical trials to promote smoking cessation, but regulatory authorities have not approved them for this purpose.

Smoking Cessation Emerging Drugs Profile

  • AXS-05: Axsome Therapeutics

Smoking Cessation Marketed Drugs

  • Varenicline (Chantix/Champix): Pfizer

Discover key developments and opportunities in the Smoking Cessation Market. Click here to learn more from DelveInsight’s latest report @ Smoking Cessation Market Size

Smoking Cessation Drugs and Companies

  • Bupropion: Rose Research Center LLC

  • Cytisinicline: Achieve Life Sciences

  • NFL-101: NFL Biosciences SAS

Smoking Cessation Drugs Uptake

  • AXS-05 is a novel, oral, investigational NMDA receptor antagonist with multimodal activity, in clinical development for major depressive disorder (MDD), Alzheimer’s disease (AD) agitation, and smoking cessation. The drug consists of dextromethorphan (DM) and bupropion and utilizes Axsome’s metabolic inhibition technology. The DM component of AXS-05 is a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, sigma-1 receptor agonist, and an inhibitor of the serotonin and norepinephrine transporters. The bupropion component of AXS-05 serves to increase the bioavailability of DM and is a norepinephrine and dopamine reuptake inhibitor. Both components are nicotinic acetylcholine receptor antagonists and have demonstrated anti-inflammatory properties. The Phase II clinical results of the AXS-05 shows a 25% greater reduction in average cigarettes per day for AXS-05 versus bupropion. AXS-05 is currently being developed for the treatment of major depressive disorder (MDD), Alzheimer’s disease agitation, and smoking cessation.

  • Cytisinicline (also known as cytisine) is an oral, plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. Achieve Life Sciences, Inc. on January, 2022 announced that the last study follow-up visit for the last subject enrolled in the ORCA-2 Phase III trial occurred in late December 2021. The ORCA-2 trial is the first Phase III trial in Achieve’s ORCA Program, designed to evaluate the smoking cessation effectiveness, safety, and tolerability of 3 mg cytisinicline taken three times daily (TID) for either 6 or 12 weeks, compared with placebo. Topline data regarding the primary results are expected in the second quarter of 2022.

  • NFL-101, NFL-101 is a patented, botanical drug candidate that aims at increasing the odds of quitting for smokers willing to quit. NFL-101 is delivered via two simple subcutaneous injections, administered one week apart at a Target Quit Date, making patient compliance a breeze. Two additional, optional injections are made available to patients still not abstinent at month three and six. Preclinical studies’ results have been approved by the French Agency for Drug Safety (ANSM). A Phase I/II clinical trial (CESTO, NCT02521701) that reported NFL-101 data in 2017 and that was implemented at the Montpellier Cancer Institute (ICM) confirmed safety and efficacy in smokers willing and trying to quit, in terms of total cessation at twelve months as well as reduction without compensatory over-smoking. A second patent was filed in 2016. A Phase II/III clinical study has been approved in France where it is currently ongoing

Smoking Cessation Market Insights

The use of nicotine sustains tobacco addiction, which in turn causes devastating health problems, including heart disease, lung disease, and cancer. Smoking harms almost every organ of the body. Quitting smoking at any age leads to significant reductions in the risks associated with smoking, and the vast majority of smokers in the United States indicate an interest in quitting.

Download DelveInsight’s Smoking Cessation Market report today and stay ahead in this rapidly evolving field. @ Smoking Cessation Clinical Trials

Scope of the Smoking Cessation Market Report

  • Coverage- 7MM

  • Smoking Cessation Companies- Rose Research Center LLC, Achieve Life Sciences, NFL Biosciences SAS, and others.

  • Smoking Cessation Therapies- Bupropion, Zonisamide, Cytisinicline, Nicoderm, Varenicline, and others.

  • Smoking Cessation Competitive Intelligence Analysis: SWOT analysis and Market entry strategies

  • Smoking Cessation Unmet Needs, KOL’s views, Analyst’s views, Smoking Cessation Market Access and Reimbursement

Download the report to understand which factors are driving Smoking Cessation market trends @ Smoking Cessation Market Trends

Table of Content

1. Key Insights

2. Executive Summary of Smoking Cessation

3. Competitive Intelligence Analysis for Smoking Cessation

4. Smoking Cessation: Market Overview at a Glance

5. Smoking Cessation: Disease Background and Overview

6. Patient Journey

7. Smoking Cessation Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Smoking Cessation Unmet Needs

10. Key Endpoints of Smoking Cessation Treatment

11. Smoking Cessation Marketed Products

12. Smoking Cessation Emerging Therapies

13. Smoking Cessation: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Smoking Cessation

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Smoking Cessation Treatment Market Size was ~USD 1800 Million in 2022, estimated DelveInsight

Steven Gillhouse Launches Brand New Personal Website

Steven Gillhouse, Cary, NC, USA
Steven Gillhouse, Vice President of Sales at Cornerstone Building Brands, is excited to announce the launch of his brand new personal website, https://www.stevengillhousenc.com/

Steven Gillhouse, Vice President of Sales at Cornerstone Building Brands, is excited to announce the launch of his brand new personal website, https://www.stevengillhousenc.com/. The website serves as a comprehensive platform to showcase Steven’s extensive experience, thought leadership, and ongoing contributions in the field of sales and marketing.

The new website offers visitors a detailed look at Steven’s professional journey, highlighting his achievements in various senior roles across leading corporations. It also features insights into his leadership philosophy, including his commitment to fostering strong relationships, driving strategic growth, and maintaining continuous improvement within his teams.

In addition to his professional achievements, the website provides a glimpse into Steven’s personal interests, such as fitness, hiking, and golf, as well as his deep commitment to philanthropy. Visitors can learn about his involvement with organizations like Habitat for Humanity and his participation in community fundraising initiatives.

Steven Gillhouse’s new website also includes a blog section where he shares his latest thoughts on industry trends, leadership strategies, and personal growth. The site is designed to be a resource for professionals looking to gain insights from Steven’s vast experience and for those interested in following his journey.

“I’m thrilled to launch this website as a way to connect with others and share my experiences in both my professional and personal life. My goal is to create a space where visitors can find valuable insights, learn more about my work, and stay updated on my latest projects and initiatives,” said Steven.

The launch of the new website marks an important step in Steven’s mission to engage with a broader audience, offering them the opportunity to benefit from his expertise and passion for leadership and community service.

About Steven Gillhouse

Steven Gillhouse, based in Cary, NC, is the Vice President of Sales at Cornerstone Building Brands. With a career marked by results-driven leadership in sales and marketing, Steven is known for his strategic approach to relationship-building and business growth. Outside of his professional endeavors, he is passionate about fitness, hiking, golf, and giving back to the community through various philanthropic efforts.

For more information, visit https://www.stevengillhousenc.com/

Media Contact
Contact Person: Steven Gillhouse
Email: Send Email
City: Cary
State: NC
Country: United States
Website: https://www.stevengillhousenc.com/

Maurice Bailey, President of Wealthy Way Financial, Interviewed on the influential Entrepreneur Podcast, Discussing How Taxes Impact Retirement

Maurice Bailey discusses how taxes impact retirement 

Listen to the interview on the Business Innovators Radio Network: https://businessinnovatorsradio.com/interview-with-maurice-bailey-president-of-wealthy-way-financial-discussing-how-taxes-impact-retirement/

Maurice Bailey, the president of Wealthy Way Financial. He delved into the critical topic of how taxes impact retirement, a subject that often gets overlooked but is essential for effective retirement planning. 

Maurice began by highlighting the inevitability of rising taxes and the importance of preparing for this reality. He pointed out that most people assume they will be in a lower tax bracket during retirement, but this is often not the case due to fewer write-offs and increased spending on activities like travel. 

One of the key takeaways from the podcast episode is the likelihood of taxes increasing in the future and the importance of planning for how they will impact retirement. Maurice Bailey, the president of Wealthy Way Financial, highlights the fact that taxes are expected to rise due to the government’s need for revenue. He emphasizes that the government typically resorts to increasing taxes as a way to generate funds, especially when spending cuts are not a viable option. 

Bailey points out that many individuals underestimate the impact of taxes on their retirement savings. He mentions that during seminars, the majority of participants believe that taxes will go up in the future. This sentiment is echoed by the understanding that the government’s tendency is to tax more rather than reduce spending significantly. 

In conclusion, Maurice underscores the critical need for individuals to anticipate and plan for potential tax increases in the future. By understanding the impact of taxes on retirement savings and implementing strategic financial strategies, individuals can better prepare for a financially secure retirement amidst changing tax landscapes. 

 
Video Link: https://www.youtube.com/embed/WbIs5hSRerk

About Maurice Bailey  

As the Safe Money Coach he has been helping individuals, families, and business owners BULLETT Proof their assets through Safe and Tax Efficient Strategies since 2003. He grew up in Massachusetts where he  attained two Associate degrees in Business Marketing and Business Management.   He currently lives in Montgomery County, Maryland with his two daughters ages 11 and 17.  He currently specializes in Optimal Income Strategies, that assures my clients pay less in income taxes while providing Guaranteed Income streams for Life.  His Social Security Income Strategies provide a way for his clients to clearly envision their Retirement from the first to their last day.  He is a Certified Financial Educator (CFED) and a member of the National Ethics Association as well as the National Association of Insurance and Financial Advisors (NAIFA). 

Learn More: https://wealthywayfinancial.com/

Recent news and interviews:

Media Contact
Company Name: Marketing Huddle, LLC
Contact Person: Mike Saunders, MBA
Email: Send Email
Phone: 7202323112
Country: United States
Website: https://www.AuthorityPositioningCoach.com

Battle Horn Brewing Raises the Bar: Crafting Revolution in Every Pint

“”We’re more than just a brewery; we’re pioneers in the world of craft brewing,” adds Dan. “Every pint is a call to arms for true beer enthusiasts, rallying them to a higher standard of brewing excellence. Our goal is not just to make great beer, but to continually redefine what great beer can be.””
Battle Horn Brewing announces a new lineup of craft beers, showcasing their commitment to innovation and quality. Blending traditional techniques with modern approaches, they create unique flavors using carefully selected local ingredients and rare hops. Their small-batch production ensures superior quality control, resulting in complex and refined tastes. Battle Horn’s sustainability focus and community engagement, including a new mentorship program, underscore their role as industry leaders.

Battle Horn Brewing, the vanguard of craft beer excellence, is proud to announce its latest lineup of meticulously crafted beers. Known for pushing the boundaries of traditional brewing, Battle Horn continues to redefine what beer can be with its bold flavors and unique styles. This announcement marks a significant milestone in the brewery’s journey to elevate the craft beer experience and challenge the palates of beer enthusiasts across the nation.

“At Battle Horn Brewing, we’re not just making beer; we’re crafting an experience,” says Dan Brewmaster, Head Brewer at Battle Horn. “Our passion lies in creating distinctive taste profiles that stand out from the uniformity of mass-produced beers. We believe that every sip should tell a story, and our latest lineup is our most ambitious narrative yet.”

The new collection features an impressive range of styles, showcasing Battle Horn’s versatility and mastery of the brewing craft. From hop-forward West Coast IPAs that burst with citrus and pine notes to rich, complex Imperial Stouts aged in bourbon barrels, the lineup caters to a wide spectrum of beer preferences. Belgian Ales brewed with traditional yeast strains offer a nod to European brewing heritage, while crisp, clean Pilsners demonstrate the brewery’s technical prowess.

Key features of Battle Horn’s brewing philosophy include:

  1. Unique Flavors and Local Ingredients: The brewery takes pride in sourcing rare hops and specialty malts, often collaborating with local farmers to obtain the freshest, highest-quality ingredients. Creative additions like locally-sourced fruits, herbs, and spices add depth and complexity to their brews.
  2. Tradition Meets Innovation: While respecting classic beer styles, Battle Horn isn’t afraid to push boundaries. Their brewing team regularly experiments with modern techniques such as dry-hopping, mixed fermentation, and even biotransformation to create beers that are both familiar and excitingly new.
  3. Small-Batch Production: Every Battle Horn brew is crafted in small batches, ensuring superior quality control and allowing for the creation of complex, refined flavors. This approach also enables the brewery to be nimble, responding quickly to emerging trends and customer feedback.
  4. Sustainability Focus: Battle Horn is committed to environmentally friendly brewing practices. The brewery has implemented water recycling systems, uses solar power for a portion of its energy needs, and has a grain recycling program that benefits local farmers.
  5. Community Engagement: The brewery regularly hosts events, tastings, and educational sessions, fostering a vibrant community of craft beer enthusiasts. Their popular “Brewer for a Day” program allows fans to get hands-on experience in the brewing process.

Battle Horn’s new releases will be available through a lottery system and investors can sign up on the Battle Horn brewing website  The launch will be accompanied by a series of tasting events across major cities, where beer lovers can meet the brewers and learn about the stories behind each new brew.

“We’re more than just a brewery; we’re pioneers in the world of craft brewing,” adds Brewmaster. “Every pint is a call to arms for true beer enthusiasts, rallying them to a higher standard of brewing excellence. Our goal is not just to make great beer, but to continually redefine what great beer can be.”

Battle Horn Brewing’s commitment to quality extends to every aspect of their ingredient sourcing and selection process. The brewery has forged strong partnerships with local farmers and hop growers, ensuring a steady supply of fresh, high-quality ingredients that capture the essence of the region’s terroir. Their hop selection process is particularly meticulous, with the brewing team conducting annual “hop rubs” to evaluate the aromatic and flavor profiles of each year’s crop. This hands-on approach allows Battle Horn to secure the most expressive and complementary hops for their brews, resulting in beers that showcase a harmonious balance of bitterness, aroma, and flavor. From the rich soils of nearby barley fields to the aromatic hop yards just miles from the brewery, every Battle Horn beer is a liquid testament to the bounty of the local agricultural landscape.

As part of their commitment to the craft beer community, Battle Horn Brewing will also be launching a mentorship program for aspiring brewers. This initiative aims to share knowledge, foster innovation, and ensure the continued growth and evolution of the craft beer industry.

For more information about Battle Horn Brewing, their latest releases, and upcoming events, visit www.battlehornbrewing.com.

Media Contact
Company Name: Battle Horn Brewing
Contact Person: Dan ODonnell
Email: Send Email
Phone: 208-488-3125
City: Boise
State: Idaho
Country: United States
Website: https://battlehornbrewing.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Battle Horn Brewing Raises the Bar: Crafting Revolution in Every Pint

Water Soluble Films Market Trends, Opportunities, Key Segmentation, Regional Growth, Leading Companies, and Forecast to 2029

“Browse 215 market data Tables and 50 Figures spread through 210 Pages and in-depth TOC on “Water Soluble Films Market””
The water-soluble films market offers eco-friendly packaging solutions. Growth is driven by sustainability trends and innovations. Asia-Pacific leads in regional growth, with North America and Europe also expanding.

In terms of value, the water soluble films market is estimated to grow from USD 441.8 million in 2024 to USD 586.4 million by 2029, at a CAGR of 5.8%. The market for water soluble films is primarily driven by rising environmental consciousness and the subsequent shift towards sustainable materials. Conventional plastic packaging has drawn criticism for its effects on the environment as it leads to plastic pollution and the buildup of non-biodegradable waste in landfills and ocean. Water soluble films, which dissolve in water and leave no toxic residues behind are a desirable alternative for companies looking to reduce their environmental impact and support global sustainability.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=31753669 

Based on type, the water-soluble films market is segmented as cold water soluble films and hot water-soluble films. From them, cold water soluble films segment accounted for largest market share, in terms of value, in 2023 and continue to dominate during the forecast period. This dominance is attributed to its adaptability and wide usage of these films in various applications. Cold water soluble films are frequently used in the detergent business for packaging of dishwashers and laundry detergents. To save energy and protect delicate fabrics, consumers are increasingly using cold wash cycles, and these cycles provide the ease of pre-measured doses while ensuring that the film dissolves entirely.

Based on application, the water soluble films market is segmented into detergent packaging, agrochemical packaging, water treatment chemical packaging, dye packaging, laundry bags, embroidery, food packaging, pharmaceutical, and other applications. The detergent packaging segment is estimated to be the largest application. Water soluble films dissolve easily in water, providing a mess-free and convenient way to use single-dose laundry and detergents. This eliminates the need for measuring and reduces the risk of spills. The need for convenient handling and less wastage of products in the developed markets will boost the use of water soluble films for detergent packaging.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=31753669 

Based on region, Asia Pacific is projected to witness the highest CAGR during the forecast period. This growth is due to the rapid industrialization, robust economic growth, increasing population, rising disposable incomes, and favorable government regulations. Consumer expenditure on packaged goods, personal care items, and medications is expanding owing to the growing middle-class incomes. The need for innovative and sustainable packaging solutions, including water-soluble films, that satisfy the demands of ecologically conscious customers drives the market.

The key players profiled in the water-soluble films industry report include Mitsubishi Chemical Group Corporation (Japan), SEKISUI CHEMICAL CO., LTD. (Japan), KURARAY CO., LTD. (Japan), AICELLO CORPORATION (Japan), Ecopol S.p.A. (Italy), Arrow GreenTech Ltd. (India), Cortec Corporation (US), Changzhou Greencradleland Macromolecule Materials Co., Ltd. (China), Jiangmen Proudly Water-soluble Plastic Co., Ltd. (China), AMC (UK) Ltd. (UK), and Noble Industries (India). These companies have reliable manufacturing facilities as well as strong global footprint across key regions, such as North America, Europe, and Asia Pacific. They have an established portfolio of reputable products and services, a robust market presence, and strong business strategies.

Inquire Now: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=31753669 

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/water-soluble-film-market-31753669.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Water Soluble Films Market Trends, Opportunities, Key Segmentation, Regional Growth, Leading Companies, and Forecast to 2029

Anti-apartheid activist holds book launch in South Africa for personal memoir

An anti-apartheid activist has published a deeply personal memoir of her journey of growth and self-discovery. Alison Weihe’s debut book – Belonging: Finding Tribes of Meaning – tells the inspiring story of her life and how she made the journey from a child who felt invisible during her upbringing in apartheid-era South Africa to being a political activist and eventually an award-winning entrepreneur. The book was launched at a high-profile event at Exclusive Books in Victoria Wharf  Cape Town on August 29, which was live-streamed on YouTube.

During her career, Alison worked for the South African president Cyril Ramaphosa when he was general secretary of the National Union of Mineworkers. A copy of her book, which includes a reference written by him, has been hand delivered to President Ramaphosa. Alison says: “Writing Belonging made sense of my whole life. From political activist to award-winning serial entrepreneur to now becoming a speaker and a writer, my life has come full circle to focusing on legacy work.  “I now hope to be a voice of hope and healing in this land at a seminal time in the history of South Africa. The book launch was an incredible event and a profound, emotional experience.”

In Belonging, Alison talks about her transformation from being a child who felt she didn’t belong, even in her own family, to becoming a global citizen passionate about uniting people separated by economic, social and cultural divides. She shares her journey of self-discovery, overcoming shame, failure and fear to finally reach a point where she felt she belonged.

At the launch of her book, Alison spoke about pivotal moments in her life, including her decision as a 19-year-old to shun the whites-only bus she was expected to take and ride with the rest of the community in the midst of the 1970s uprisings. She also talked about how a mistake she made when working for a trade union left her feeling such deep shame, she considered ending her own life.

After her career as a trade union activist and political journalist, the 65-year-old, who lives in Johannesburg, spent 25 years as an entrepreneur in the South African construction industry. In the last six years, she has become a speaker and award-winning coach, empowering others to live a life of meaning. Alison is a passionate believer in owning your story, living with grace, and stepping into the power of who you were truly meant to be. 

Belonging: Finding Tribes of Meaning is available now at https://alisonweihe.com

Media Contact
Company Name: Dauntless PR
Contact Person: Luana Ribeira
Email: Send Email
Phone: 0330 043 4102
Country: United Kingdom
Website: https://dauntlesspr.com/

Amazing Presentation at Investment Conference with Acquisition Plans for Clinics Generating $100 Million in 2025 to Complement Drug Development for Bipolar Depression and Related Disorders: NRXP

Substantial Funding Agreements, Debt Resolution and Successful Clinical Trial Progress Towards Accelerated Drug Approval

• Developing Therapeutics for the Treatment of CNS Disorders, Specifically Suicidal Bipolar Depression, Chronic Pain and PTSD.

• Company Funded for New Drug Applications (NDAs) for NRX-100 (ketamine) and NRX-101

• Participation at the H.C. Wainwright 26th Annual Global Investment Conference. 

• Potential Acquisition and Financing Agreements for $30 Million in Currently-Operating Interventional Psychiatry Clinics.

• Audit of HOPE Therapeutics Subsidiary Complete, SEC Filing of Spinout Planned for Current Quarter. 

• Secured $10.8 – $16.3 Million Convertible-Debt Funding from an Institutional Investor. 

• Plans to file New Drug Application for Accelerated Approval under Breakthrough Therapy Designation and Priority Review of NRX-101. 

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain

NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

Participation at the H.C. Wainwright 26th Annual Global Investment Conference 

NRXP has been featured at the H.C. Wainwright 26th Annual Global Investment Conference. The conference is being held on September 9-11, 2024. 

The in-person venue for the event is the Lotte New York Palace Hotel in New York City located at 455 Madison Avenue. Virtual participation will be staged simultaneously with over 550 company presentations scheduled as live feed or available on-demand.

Key points covered in the NRXP Presentation include the following:  

NRXP is developing a pair of promising new treatments for bipolar depression and suicidal ideation.

Nearly 4 million Americans planned suicide in 2022, with estimates suggesting that two-thirds of cases are associated with a mood disorder.

NRX-101 is an oral, fixed-dose combination of D-cycloserine and lurasidone being developed to treat treatment-resistant bipolar depression with suicidality or akathisia.

NRX-100 is an IV ketamine formulation being studied as a treatment for acute suicidal crises in all forms of depression, including bipolar depression.

The potential of these two NRXP therapies is monumental. Bipolar disorder presents a significant global health challenge, mostly because of its close ties to higher suicide risk during depressive episodes. Suicidal Depression affects millions of people every year; a pharmacologic treatment is a critical need.

The lack of FDA-approved pharmacological treatments targeting suicidal and bipolar depression with suicidality or akathisia in today’s market underscores the need for more innovative therapies. And, if approved, these new NRXP treatments would be the first FDA-approved pharmaceutical regimens developed to treat these in patients struggling with suicidal behavior, ideation, or depression. 

It’s not an overstatement to say that NRXP could not only improve the quality of life for millions of people. It would also significantly cut the suicide rates among those affected.

NRXP Investors can listen to the Company’s full presentation via the following link www.hcwevents.com/annualconference. Access to the NRXP presentation can also be found at https://ir.nrxpharma.com/events or https://acrobat.adobe.com/id/urn:aaid:sc:VA6C2:b7b93ceb-6ffa-44f7-b79c-76820e3e225d 

Potential Acquisition and Financing Agreements for $30 Million in Currently-Operating Interventional Psychiatry Clinics

On August 26th NRXP announced signing a non-binding Term Sheet for non-dilutive, nonconvertible debt acquisition funding of its first interventional psychiatry clinics (ketamine clinic acquisitions), together with the signing of a Term Sheet for five currently operational clinics in the Western United States. In addition to the currently-signed non-binding Term Sheet, NRXP has been offered non-binding lending commitments it believes are sufficient to assemble/acquire a network of operational clinics with revenues in excess of $100 million. NRXP anticipates potential operations in the United States, France, and the United Kingdom. 

This non-dilutive acquisition funding is in addition to the over $60 million in potential equity funding previously offered upon public listing of HOPE Therapeutics shares on a public exchange. Additional information to be presented by NRXP at upcoming HC Wainwright Annual Global Investment Conference in New York, September 9-11, 2024.

For more information on $NRXP visit: https://www.nrxpharma.com/ and https://compasslivemedia.com/case-study/nrx-pharmaceuticals/

DISCLAIMER: https://corporateads.com/disclaimer/

Disclosure listed on the CorporateAds website

Media Contact
Company Name: NRx Pharmaceuticals, Inc.
Contact Person: Matthew Duffy, Chief Business Officer
Email: Send Email
Phone: 484 254 6134
Address:1201 Orange Street Suite 600
City: Wilmington
State: Delaware 19801
Country: United States
Website: https://www.nrxpharma.com/

Sepsis Treatment Market Treatment Market across the 7MM is projected to experience growth during the Study Period (2020-2034)

“Sepsis Therapies such as GIAPREZA (angiotensin II), VBI-S, Nangibotide, and others”

The Sepsis Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Sepsis therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

DelveInsight’s “Sepsis Market Insight, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of Sepsis, historical and forecasted epidemiology as well as the Sepsis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Unlock detailed insights into the Sepsis Market by downloading the comprehensive report from DelveInsight @ Sepsis Therapeutics Market

Key Takeaways from Sepsis Market Report

  • The Growth of the Sepsis Market is expected to be primarily driven by an expanding patient population, and advancement in diagnostic methods.

  • The leading Sepsis Companies such as La Jolla Pharmaceuticals, Vivacelle Bio, Inotrem SA, and others.

  • Promising Sepsis Therapies such as GIAPREZA (angiotensin II), VBI-S, Nangibotide, and others.

  • According to DelveInsight’s analysis, the incident cases of Sepsis in the US were 1,938,855 in 2022 and are estimated to increase during the forecast period (2023-2034).

  • According to DelveInsight’s analysis, the female population in the US was dominant over the male population with 984,938 and 953,917 cases respectively in 2022. These cases are anticipated to grow in the forecast period.

  • August 2024:- Grand Medical Pty Ltd.- A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Dose Exploration Clinical Trial Evaluating the Efficacy, Safety, and Pharmacokinetic Characteristics of STC314 Injection Administered Intravenously in Sepsis Patients.

  • August 2024:- Vivacelle Bio- This study is being conducted to evaluate the safety and effectiveness of VBI-S in elevating the blood pressure of septic shock patients with absolute or relative hypovolemia. This study is being conducted to evaluate the safety and effectiveness of VBI-S in elevating the blood pressure of septic shock patients with absolute or relative hypovolemia.

Gain a competitive edge in the Sepsis Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Sepsis Treatment Drugs

Sepsis Treatment Market

Sepsis treatment varies, depending on the site and the cause of the initial infection, the organs affected and the extent of any damage. Sepsis should be treated as a medical emergency and treated as quickly and efficiently as possible as soon as it has been identified. Sepsis treatment is examined under two categories with appropriate antimicrobial treatment and all-purpose supporting treatment.

Sepsis Marketed Drugs Profile

  • GIAPREZA (angiotensin II): La Jolla Pharmaceuticals

  • VBI-S: Vivacelle Bio

  • Nangibotide: Inotrem SA

Discover key developments and opportunities in the Sepsis Market. Click here to learn more from DelveInsight’s latest report @ Sepsis Market Size

Sepsis Market Insights

Overall, the global as well as 7MM Sepsis therapeutics market is further expected to increase accrediting the major drivers such as rising incident population, technological advancements, increased funding for new drug development and clinical trials, increasing awareness among common people, increasing research activities and upcoming therapies during the forecast period [2023-2034].

Sepsis Market Dynamics

The Sepsis treatment market dynamics is anticipated to change during the forecast period as companies across the 7MM are diligently working towards the development of novel treatment options to combat the existing treatment based unmet needs. Key players, such as Vivacelle Bio, Inotrem SA, and others are involved actively in developing potential treatment scopes.

Download DelveInsight’s Sepsis Market report today and stay ahead in this rapidly evolving field. @ Sepsis Clinical Trials

Scope of the Sepsis Market Report

  • Coverage- 7MM

  • Sepsis Companies- La Jolla Pharmaceuticals, Vivacelle Bio, Inotrem SA, and others.

  • Sepsis Therapies- GIAPREZA (angiotensin II), VBI-S, Nangibotide, and others.

  • Sepsis Competitive Intelligence Analysis: SWOT analysis and Market entry strategies

  • Sepsis Unmet Needs, KOL’s views, Analyst’s views, Sepsis Market Access and Reimbursement

Download the report to understand which factors are driving Sepsis Market Trends @ Sepsis Market Trends

Table of Content

1 Key Insights

2 Report Introduction

3 Executive Summary

4 Key Events

5 Epidemiology and Market Forecast Methodology

6 Sepsis Market Overview at a Glance

7 Sepsis: Disease Background and Overview

8 Treatment and Medical Management

9 Epidemiology and Patient Population of Sepsis

10 Patient Journey

11 Marketed Drugs

12 Key Cross Competition

13 Key Emerging Therapies

14 Sepsis: Seven Major Market Analysis

15 KOL Views

16 SWOT Analysis

17 Unmet Needs

18 Market Access and Reimbursement

19 Appendix

20 DelveInsight Capabilities

21 Disclaimer

22 About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Sepsis Treatment Market Treatment Market across the 7MM is projected to experience growth during the Study Period (2020-2034)

TELECO Now Offering Sangoma’s UC Cloud and On-Premises Platforms to Dealers

“Sangoma’s Ultimate UC Solution Offered by TELECO”

September 10, 2024 – TELECO, a leading provider of business communication solutions, is excited to announce that it is now offering Sangoma’s Unified Communications (UC) Cloud and On-Premises platforms to its dealer network. These comprehensive platforms are designed to meet the diverse needs of small to medium-sized businesses, providing powerful tools to enhance productivity and streamline operations.

Sangoma UC Cloud powered by Switchvox is an ideal Unified Communications as a Service (UCaaS) platform, perfect for businesses looking for a user-friendly, feature-rich system that can be quickly deployed in the cloud. With its intuitive interface and robust capabilities, Sangoma UC Cloud allows businesses to improve communication and collaboration without extensive technical expertise. This turnkey solution is easy to set up and offers the flexibility and scalability that growing businesses require.

For businesses that prefer more control over their phone system, Sangoma UC On-Prem powered by Switchvox delivers the same powerful features as the cloud version, along with the advantage of managing updates and system integrations directly. This solution is perfect for companies that need a fully featured VoIP phone system deployed on-site, allowing administrators to customize and manage the system according to their specific needs.

“By offering both types of deployments of Sangoma UC Cloud and On-Prem, we are providing our dealers with versatile platforms that cater to the varied requirements of their customers,” said Mark Williams, Chief Development Officer at TELECO. “Whether a business prefers the convenience and flexibility of the cloud or the control of an on-premises system, Sangoma UC provides a robust, feature-rich platform that enhances communication and collaboration, driving business success.”

TELECO dealers can now offer these cutting-edge platforms to their customers, ensuring that small to medium-sized businesses have access to the best communication tools available. With Sangoma UC, businesses can seamlessly integrate voice, video, and messaging, all from a single, unified platform.

For more information about TELECO’s new offerings and how they can benefit your business, please contact 800.800.6159

About TELECO:

TELECO is a leading provider of telecommunications solutions, offering a wide range of services including Public Safety and Cellular DAS (Distributed Antenna System), DAS Field testing, Site Survey, Video Surveillance, Access Control, Structured Cabling, Business Phones, Managed IT and cloud services. With a focus on innovation, reliability, and customer satisfaction, TELECO is dedicated to helping businesses and organizations achieve their connectivity goals.

About Sangoma:

Sangoma (TSX: STC; Nasdaq: SANG) is a leading business communications platform provider with solutions that include its award-winning UCaaS, CCaaS, CPaaS, and Trunking technologies. The enterprise-grade communications suite is developed in-house; available for cloud, hybrid, or on-premises deployments. Additionally, Sangoma’s integrated approach provides managed services for connectivity, network, and security.

A trusted communications partner with over 40 years on the market, Sangoma has over 2.7 million UC seats across a diversified base of over 100,000 customers. Sangoma has been recognized for nine years running in the Gartner UCaaS Magic Quadrant.

As the primary developer and sponsor of the open source Asterisk and FreePBX projects, Sangoma is determined to continuously drive innovation in communication technology.

For more information, visit www.sangoma.com

Media Contact
Company Name: TELECO, Inc.
Contact Person: Mark Williams
Email: Send Email
Phone: (800) 800-6159
Address:430 Woodruff Road Suite 300
City: Greenville
State: SC
Country: United States
Website: https://www.teleco.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: TELECO Now Offering Sangoma\’s UC Cloud and On-Premises Platforms to Dealers

Surging Subscriptions in New Artificial Intelligence Entertainment Service for Sports Enthusiasts (NFL, NBA, UFC, MLB, MLS) Plus Fantasy Leagues: IDVV

• Engaged in Locating, Acquiring and Partnering with Established Companies, Brands and Technologies, Particularly, in the Artificial Intelligence (AI) Sector.

• Applications for Research and Odds Analysis in Fantasy Leagues and Professional Sports (NFL, NBA, UFC, MLB, MLS).

• Subscriptions Top 4000 for Free Beta Testing Version Recently Launched. 

• Plans to Convert Subscribers to Several Paid Options Towards End of October.

• Using the NFL Football and Fantasy Betting Season as a Driving Catalyst. 

• Paid Subscription Service Coming with Interactive Sports Bot, Plus Expansion into Hockey and Basketball. 

• Pro Platform has a Negotiable Signup Fee Up to $10,000 Per License Along with a Monthly Subscription of $1000 to $2000.

International Endeavors Corporation (OTC: IDVV) is engaged in locating, acquiring and partnering with established companies, brands and technologies, particularly in the Artificial Intelligence (AI) sector. IDVV has developed BOT technology and Automated processes related to crypto. IDVV sells or licenses these technologies. IDVV has focused on several action items including solidifying WITech.ai as the main holding of the company, eliminating costs, and expanding its product offerings while preparing for acquisitions.

The IDVV WITech division stands at the forefront of the AI revolution, striving to bridge the gap between human ingenuity and artificial intelligence. The IDVV WITech mission is to empower clients by delivering state-of-the-art AI integrated applications that transform Chat Bots, Video Generation, and Content Creation into powerful tools for business growth and personal expression. IDVV is dedicated to developing solutions that enhance communication, foster creative processes, and streamline the distribution of content across diverse platforms.

IDVV commitment extends beyond the mere application of technology; it is about creating a symbiotic relationship where AI complements human talent, enabling our customers to achieve more with less effort. IDVV believes in customizing its AI-driven applications to fit the unique challenges and objectives of each client, ensuring that every solution is as unique as the problem it solves. With a focus on user-friendly interfaces and seamless integration, IDVV products are designed to be accessible to all, regardless of technical expertise. 

IDVV has now launched winnerswaygers.com in a free beta mode thus expanding its AI’s ability into sports applications. The IDVV WITech division plans to expand the service quickly into a subscription based model featuring all major sports using the popularity of the NFL football and fantasy betting season as a catalyst to make users aware of the service.

Update on Winners Waygers AI Powered Sports Entertainment Assistant

On September 10th IDVV announced it had received additional pro subscribers, and its free beta version has topped 4000 subscribers.

Current IDVV subscribers are being given picks that the AI is generating for the current NFL season, and plans are to convert subscribers to several paid options towards the end of October as the AI learns more data during the current season and becomes more efficient in its strategy. Last season the AI had over a 60% win rate, with an increasingly better win rate as the season progresses and the AI is able to use more up to date information. The current IDVV focus is building subscribers while perfecting the AI’s thought process.

The IDVV Pro platform is used by professionals that helped to develop the tools and datasets for the AI. The IDVV Pro tools do not make picks for professionals, but instead help them to acquire data at a much faster pace and allow them to increase their action. IDVV anticipates reaching up to 100 Pro subscribers by year end. Due to that nature of the community, Pro subscribers are acquired by referrals. Each paying a negotiable signup fee of up to $10,000 per license along with a monthly subscription of $1000 to $2000.

IDVV Winners Waygers Video


Video Link: http://player.vimeo.com/video/999064151

DISCLAIMER: https://corporateads.com/disclaimer/

Disclosure listed on the CorporateAds website

Media Contact
Company Name: International Endeavors Corporation
Contact Person: Jillian White, CEO
Email: Send Email
Phone: +1 833-705-0022
Address:43020 Black Deer Loop Suite 103
City: Temecula
State: CA 92590
Country: United States
Website: https://witech.ai/